Research programme: serotonin 6 receptor modulators - AMRI

Drug Profile

Research programme: serotonin 6 receptor modulators - AMRI

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator AMRI
  • Class
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cognition disorders
  • Discontinued Obesity

Most Recent Events

  • 12 Sep 2016 Preclinical development for Cognition disorders is still ongoing in USA (AMRI pipeline, September 2016)
  • 12 Sep 2016 Research programme: serotonin 6 receptor modulators - AMRI is available for licensing as of 12 Sep 2016. http://www.amriglobal.com/partnering/Alzheimers_5-HT6_Drug_Research_82_pg.htm
  • 16 Jul 2016 No recent reports of development identified for research development in Cognition-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top